SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-23-239550
Filing Date
2023-09-21
Accepted
2023-09-21 16:01:49
Documents
5
Period of Report
2023-11-15

Document Format Files

Seq Description Document Type Size
1 PRE 14A d529157dpre14a.htm PRE 14A 131217
2 GRAPHIC g529157dsp018.jpg GRAPHIC 2277
3 GRAPHIC g529157dsp018a.jpg GRAPHIC 4005
4 GRAPHIC g529157dsp018b.jpg GRAPHIC 981
5 GRAPHIC g529157g01p01.jpg GRAPHIC 64648
  Complete submission text file 0001193125-23-239550.txt   231916
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39536 | Film No.: 231269136
SIC: 2836 Biological Products, (No Diagnostic Substances)